Cytek Biosciences (CTKB) Total Liabilities (2020 - 2026)

Cytek Biosciences (CTKB) has 7 years of Total Liabilities data on file, last reported at $121.5 million in Q1 2026.

• For the quarter ending Q1 2026, Total Liabilities rose 17.96% year-over-year to $121.5 million; the trailing twelve-month figure through Mar 2026 stood at $121.5 million (up 17.96% YoY), and the FY2025 full-year result was $119.8 million, up 15.46% from the prior year.
• Total Liabilities for Q1 2026 stood at $121.5 million, up from $119.8 million in the prior quarter.
• Across five years, Total Liabilities topped out at $121.5 million in Q1 2026 and bottomed at $78.4 million in Q1 2022.
• The 5-year median for Total Liabilities is $101.4 million (2023), against an average of $101.4 million.
• The widest annual swing landed in 2022, when Total Liabilities surged 7943.7%; it then decreased 6.22% in 2024.
• A 5-year view of Total Liabilities shows it stood at $93.9 million in 2022, then gained by 7.95% to $101.4 million in 2023, then climbed by 2.34% to $103.8 million in 2024, then increased by 15.46% to $119.8 million in 2025, then grew by 1.39% to $121.5 million in 2026.
• The last three Total Liabilities figures came in at $121.5 million (Q1 2026), $119.8 million (Q4 2025), and $116.3 million (Q3 2025), per Business Quant data.

Peer Comparison